U.S. health officials have lifted an 11-day pause on Johnson & Johnson vaccinations following a recommendation by an expert panel.
Advisers to the Centers for Disease Control and Prevention said Friday the benefits of the single-dose COVID-19 shot outweigh a rare risk of blood clots.
Panel members said it’s critical that younger women be told about that risk so they can decide if they’d rather choose another vaccine. The CDC and Food and Drug Administration agreed.
European regulators earlier this week made a similar decision, deciding the clot risk was small enough to allow the rollout of J&J’s shot.
Following a thorough safety review, the FDA and @CDCgov have determined that the recommended pause regarding the use of the Johnson & Johnson (Janssen) #COVID19 Vaccine in the U.S. should be lifted and use of the vaccine should resume. https://t.co/QSuse0jyas pic.twitter.com/cdIH1yHa8s
— U.S. FDA (@US_FDA) April 23, 2021